← Browse by Condition
Medical Condition

thrombotic microangiopathies

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for thrombotic microangiopathies sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — thrombotic microangiopathies Clinical Trials

How many clinical trials are currently recruiting for thrombotic microangiopathies?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for thrombotic microangiopathies, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for thrombotic microangiopathies?
thrombotic microangiopathies research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a thrombotic microangiopathies clinical trial?
Eligibility criteria for thrombotic microangiopathies trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
The First Affiliated Hospital of Soochow University 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
Omeros Corporation 1 trial

Recruiting Clinical Trials

NCT05634928
Recruiting
Construction of a Database for TMA
Enrollment
500 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT07205861
Recruiting
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Enrollment
1,200 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT05855083 Phase 2
Recruiting
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Enrollment
18 pts
Location
United States, Germa...
Sponsor
Omeros Corporation
View Trial →

Related Conditions

thrombotic thrombocytopenic purpura ttp (1) immune thrombotic thrombocytopenic purpura (1) microangiopathy thromboic (1) cardiovascular diseases (1) autoimmune diseases (1) rare diseases (1) neurological manifestations (1) hematopoietic stem cell transplantation (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology